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Abstract: This is the first prospective study carried out in Argentina and Latin America to provide the impact of epilepsy 
throughout the childbearing years life of women, and pregnancy outcome in a population of pregnant women with diagno-
sis of epilepsy and antiepileptics drugs (AEDs). Ninety-four women were studied prospectively at the Epilepsy Center, the 
largest in Argentina. Of the 94 women examined in this study only 10% planned their pregnancy and received folic acid 
before conception. 
More than half of women in our study were on monotherapy, with the most frequently prescribed drugs being carba-
mazepine and valproic acid. In all, 90.4% of the women had a normal pregnancy and delivery. There were 8.5% sponta-
neous abortions. Major congenital malformations (MCM) was detected in 10.6% of newborns at birth; in the general 
population it varies between 1.6-3.2%. The results from this study are helpful in the highlighting correct gaps in knowl-
edge in this population group. 
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1. INTRODUCTION 
Epilepsy is the most common serious neurological disor-
der and is one of the world’s most prevalent non-
transmissible diseases [1, 2]. Over four-fifths of the 50 mil-
lion people diagnosed with epilepsy live in developing coun-
tries. People with epilepsy continue to be stigmatized and 
have a lower quality of life than people with other chronic 
illnesses. Epilepsy has different implications for life and 
well-being in men and women; a major concern is the care of 
women with epilepsy during pregnancy and throughout all 
phases of their reproductive life. A recent report from the 
World Health Organization on gender inequality in health 
indicates that women have increased exposure and vulner-
ability to risk and limited access to health care and informa-
tion [3]. There is deficient evidence and data for the clinical 
care of female with epilepsy in Argentina and Latin Amer-
ica. In this context, the main purpose of this study was to 
investigate the impact of epilepsy throughout the childbear-
ing years of women’s lives and on pregnancy outcomes. 
2. METHODS 
2.1. Population 
This investigation was performed at the Epilepsy Center 
of Ramos 
Mejía Hospital (EC), which is the largest epilepsy center 
in Argentina. Patients are referred to the EC by neurology 
departments from different parts of the country; a minority 
of patients also attend the EC spontaneously.  
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The women admitted to this study were all examined by 
the same group of neurologists who diagnosed epilepsy and 
monitored the women throughout pregnancy and up to one-
year post delivery.  
All patients who participated in this study were asked to 
complete a self-questionnaire in order to gain more insight 
into gender-related aspects of family planning, contraceptive 
use and information about epilepsy and potential risks of 
antiepileptics drugs (AEDs) effects.  
The study was conducted with the approval of the ethics 
committee of Ramos Mejía Hospital in accordance with the 
ethical standards of the 1964 Declaration of Helsinki. All 
participants submitted informed consent. 
2.2. Patient Selection 
Between December 2002 and June 2009, 129 women di-
agnosed with epilepsy and being treated with AEDs were 
admitted to the Epilepsy and Pregnancy outpatient clinic 
(EP) created in 2002. Since 2002, the EP has been advertis-
ing its activities at the Neurological National Congress, the 
Epilepsy Congress, on its website and through the mass me-
dia. EP advertisements were also present in the waiting room 
of the EC. These advertisements made it clear that patients 
could attend the EP without an appointment if they were 
pregnant or planning on becoming pregnant. Staff at the hos-
pital’s obstetric unit were also informed of EP activities. 
In this study, 94 pregnant women taking AEDs at the 
time of conception were included prospectively according to 
the following criteria: 
1. Female  aged  18–40 
2.  Clinical diagnosis of epilepsy  
3. AEDs  treatment 64     The Open Neurology Journal, 2011, Volume 5  Kochen et al. 
4.  Confirmed pregnancy  
5.  Agreed to complete survey questionnaire 
6.  Follow-up every trimester until delivery  
2.3. Diagnosis of Epilepsy 
All patients included in this study underwent a complete 
clinical and neurological assessment of seizure semiology. 
Additional studies, including interictal EEG and MRI, were 
used to confirm the type of epilepsy, consistent with stan-
dardized medical procedures [4]. 
2.4. Diagnosis of Pregnancy 
All women admitted to the EP were incorporated accord- 
ing to the prospective protocol EURAP, an international   
registry of Antiepileptic Drugs and Pregnancy [5]. Our EP is  
the national coordinator for EURAP. Most patients were   
referred to the EP by an epileptologist of the EC, while   
others came spontaneously in response to the advertising.   
EURAP protocol was adhered to from the beginning of the  
study. All aspects related to epilepsy, pregnancy, childbirth  
and the newborn (until one year of age), and clinical and   
AEDs impact were prospectively assessed. Information on  
Table 1.  Self-Completed Questionnaire 
Questions:     Patients (Percentage) 
1- Epilepsy, as a condition, can have an impact on the following 
(check all that apply): 
0-None  
   1-Pregnancy   75 (80%) 
 2-Your  own  health  - 
  3- Baby’s health  84 (90 %) 
  4- Birth control  56 (60%) 
   5- Sexuality  - 
2- Antiepileptic drugs, used to treat epilepsy, can have an impact on 
the following (check all that apply) 
0-None  
 1-Pregnancy  40% 
   2-Your own health  - 
  3- Baby’s health  84 (90%) 
  4-Birth control  56 (60%) 
   5-Sexuality  - 
 3- What kind of birth control did you use?  1-Barrier  10 (9%) 
  2-Birth control pill  9 (8%) 
   3-Other   
   4-None  75 (80%)  
 4- Did you plan your pregnancy?  1-Yes  9 (10%) 
 2-No  85  (90%) 
5- When was the first time you discussed family planning with your 
physician?  
1-At first visit   
 
  2-After several visits  10 (10%) 
  3-During pregnancy  47 (50%) 
   4-Never  37 (40%) 
6- Have you ever voluntarily terminated a pregnancy?  1-Yes  1 (1%) 
 2-No   
7- Has your partner used any contraceptive methods?  1-Yes  56p (60%) 
 2-No  38p  (40%) 
 8- Are you employed?  1-Yes  28 p (30%)  
  2-Housewives  55 p (58%) 
  3- No  11 p (12%) 
9- Are you married or living as married?  1-Yes  70 (75%) 
 2-No  24  (25%) Pregnant Women with Epilepsy in a Developing Country  The Open Neurology Journal, 2011, Volume 5    65 
patient demographics, type of epilepsy, seizure frequency, 
family history of malformations, drug therapy, AEDs (type 
and dose during the follow up), start date of folic acid (FA) 
supplementation, ultrasound examination, or other methods 
of amniocentesis and of other potential risk factors was re-
corded in the registry. Follow-up data were collected once 
each trimester, at birth and at one year after delivery and also 
recorded in the registry. 
The attending neonatologist reported the abnormalities 
observed in the newborns. The final assessment and classifi-
cation of the type of malformation was conducted by the 
central project commission of EURAP using EUROCAT 
coding [6, 7].  
2.5. Gender Aspects 
In order to assess qualitative aspects related to gender 
such as family planning, contraceptive use and information 
about epilepsy and potential risks of AEDs effects, we used a 
self-questionnaire that we had designed for this purpose (Ta-
ble 1). The questionnaire also addressed aspects related to 
social life, marital status and employment. All the patients 
included in this study completed the survey.  
2.6. Data Analysis 
The Student’s t test was used to compare quantitative 
variables, and Fisher’s exact test was used to compare quali-
tative variables. Binary logistic regression was applied to 
qualitative variables, and the odds ratio (OR) and 95% con-
fidence interval (95% CI) were determined. SPSS for Win-
dows (version 10.0) was used for statistical analysis. 
3. RESULTS 
For this study, 94 pregnant women diagnosed with epi-
lepsy who were receiving AEDs were selected and prospec-
tively included between December 2002 and June 2009. An 
additional 7 patients were excluded due to ongoing preg-
nancy, and 28 women were not followed-up.  
The survey (Table 1) indicated that 90% (n=85) of 
women studied had not planned their pregnancies; this rate is 
similar to that observed in the general population [9]. When 
asked, if patients used any contraceptive methods, 80% of 
patients (n=75) answered negatively; however, when asked if 
their partners used any contraceptive method, 60% of them 
(n=56) claimed they used barrier methods as a means of con-
traception. This apparent contradiction may be due to lack of 
information and sexual education. In relation to epilepsy, 
90% of women (n=84) were concerned about their babies 
"health" and the toxic effects of AEDs that they were ex-
posed during pregnancy. However, only one patient had his-
tory of a voluntarily interrupted pregnancy, probably because 
abortion is illegal in Argentina. Information about family 
planning was received by only 60% of patients (n=57), the 
most during pregnancy. In relation to employment, 30% 
(n=25) of patients were employed, 12% (n=11) were unem-
ployed and the remaining patients described themselves as 
housewives. 
In terms of education, 50% of patients (n=47) had 
reached a secondary school level, which is similar to the 
general population [8]. Regarding ethnicity, 68% (n=64) of 
patients were white, 25% (n=24) were of mixed descent 
(asian and black) and 6% (n=6) were of indigenous origin 
(Table 2).  
In relation to epilepsy, 70% of patients (n=66) had focal 
epilepsy, 24.4% (n=23) had generalized epilepsy and 5.5% 
(n=5) were unclassified (Table 2). 
Seizure control during the second and third trimester was 
compared with that during the first trimester. It was observed 
that 55.3% of patients (n=52) maintained the same seizure 
frequency, 27.6% (n=26) improved and 17% (n=16) deterio-
rated; there was one case of non-convulsive status epilepti-
cus related to a lowering of VPA dose. Forty-five percent of 
patients (n=43) were seizure free during the entire pregnancy 
(Table 2). 
 In regard to treatment, 65.9% (n=62) patients received 
monotherapy, 48.3% (n=30) were treated with carba-
mazepine (CBZ), the most frequently drug used, and 32.2% 
(n=20) were treated with valproic acid (VPA). In the group 
of patients receiving polytherapy, the most frequent drug 
combinations were VPA and benzodiazepines (BDZ), CBZ 
and phenobarbital (PHB), and CBZ and VPA. In total, 16% 
of patients (n=15) received “second-generation” AEDs 
(lamotrigine (LMT), topiramate (TPM), levetiracetam): 2 
patients received these drugs as monotherapy, and 13 pa-
tients received them in polytherapy. Treatment remained 
unchanged in 54.2% of patients (n=51), was reduced in 
28.7% of patients (n=27) who were free of seizures at the 
beginning of pregnancy, and was augmented in 17% of pa-
tients (n=16) who showed an increase in the frequency of 
seizures.  
At the time of enrollment, 70% of patients (n=66) were in 
the 16th week of gestation, 25.5% (n=24) were in their sec-
ond trimester and 4.4% of patients (n=4) were in their third 
trimester of gestation. Only 10% (n=9) received FA supple-
mentation before conception. These women were admitted to 
EC for family planning, and the information included in the 
record of each patient. Fifty-five percent of patients (n=52) 
received FA during the first 16 weeks of pregnancy. 
Ninety percent of patients (n=86) had normal pregnancies 
and deliveries. There were 8 patients who underwent sponta-
neous abortions. Of these 8 patients, 4 were receiving mono-
therapy with CBZ (1200 mg/d; 600 mg/d; 400 mg/d and 200 
mg/d), 3 were receiving monotherapy with VPA (800 mg/d) 
and the remaining patient received polytherapy with LMT 
(450 mg/d) and clonazepam (CLZ) (2 mg/d). Of the 4 pa-
tients receiving CBZ monotherapy only 2 received FA. 
In relation to prenatal diagnosis, no more than 59.6% of 
patients (n=56) underwent low-resolution ultrasound exami-
nation, which was normal in all the cases analysed. Only one 
patient was examined for chromosomal abnormalities. 
 Of the 86 births, there were two cases of perinatal death. 
One of the patients received polytherapy with CBZ (1000 
mg/d) and TPM (200 mg/d), and the other one was treated 
with CLZ (2 mg/d). Neither of these patients received folic 
acid because their pregnancies were not planned. The causes 
of death were prematurity and bronchial aspiration, respec-
tively. No autopsies were performed in either case. 
MCMs were detected in 10.6% (n=9) of the newborns at 
birth. Ultrasounds had been conducted on 8 of the mothers 
from this group, all of which were normal. Of these 9 pa-66     The Open Neurology Journal, 2011, Volume 5  Kochen et al. 
tients, 3 patients received monotherapy with VPA, 2 patients 
received monotherapy with CBZ, 2 patients received poly-
therapy with phenytoin and TPM, 1 patient received poly-
therapy with CBZ and TPM, and the final patient received 
polytherapy with CBZ and PHB. Two patients received FA. 
Of all live births, only 20 could be evaluated during the first 
year after birth. All were normal.  
4. CONCLUSIONS  
This was the first prospective study carried out in Argen-
tina and Latin America to provide qualitative information 
regarding gender issues in a population of pregnant women 
with diagnosis of epilepsy and receiving AEDs.  
Ninety-four pregnant women with a diagnosis of epilepsy 
receiving AEDs were studied prospectively between Decem-
ber 2002 and June 2009 according to the EURAP protocol, 
an international registry of Antiepileptic Drugs and Preg-
nancy [5]. Although we attempted to provide access to our 
facility to women who were pregnant or planning on becom-
ing pregnant, we found it very difficult to recruit this popula-
tion, and the reasons for this difficulty remain unclear. A key 
reason for this may be due to fears the mother may have had 
for the health of her baby. As evidenced by the responses to 
the questions in our survey, many female EC patients discon-
tinued the use of AEDs while they were pregnant, and they 
returned to EC after delivery. Another cause may be a feel-
ing of guilt on the part of the mother for not having planned 
the pregnancy. Responses to the questionnaire indicated that 
most women were primarily concerned about the babies 
"health" once they learned of their pregnancy; however, only 
10% planned their pregnancy, and only one patient reported 
the voluntary termination of a pregnancy. The results from 
this study are applicable to other non-epileptic inhabitants of 
Argentina, particularly those in the lower income population, 
more than 60% of whom visit the hospital. Other factors 
likely to contribute to these findings are the illegality of 
abortion, the fairly recent implementation of family planning 
programs and fact that only a little more than half of the 
women talked to their neurologist and preconception coun-
seling and received information during pregnancy. In rela-
tion to epilepsy, most patients presented with partial sei-
zures, as our population in EC [4]. Nearly half of women 
were seizure free during the entire pregnancy, and seizure 
frequency did not change during pregnancy. There was one 
case of non-convulsive status epilepticus due to the lowering 
of AED. The seizure frequency is similar to other reports 
[10-13]. In regard to treatment, more than half of women 
were on monotherapy, with CBZ being the most frequently 
drug used, followed by VPA, while 77% received monother-
apy [7]. The most common combinations in the group re-
ceiving polytherapy were VPA and BDZ, and CBZ and 
PHB. Sixteen percent of patients received second-generation 
AEDs, which is similar percentage to the general population 
of EC. The limited use is probably due to their high cost, not 
to special considerations for pregnancy.  
In relation to pregnancy at the time of enrollment, only 
10% of patients had planned their pregnancy and received 
FA supplementation before conception. Seventy percent of 
women were in the 16th week of gestation or less. More than 
Table 2.  Demographic Data 
   Pat.  Percent 
 Ethnicity  White  64  68% 
   Mixed Origin  24  25% 
   Aboriginal  6  6% 
 Educational Level  Primary  33  35% 
   Secondary  47  50% 
 Tertiary  12  13% 
   Below-primary  2  2% 
Gestational age at admission  1st Trimester  66  70% 
 2nd  Trimester  24  24% 
 3rd  Trimester  4  5% 
Type of Epilepsy  Focal  66  70% 
 Generalized  23  24% 
   Undetermined  5  5% 
Seizure Control  Equal  52  55% 
 Best  26  27% 
   Worse  16  17% 
Treatment Scheme  Monotherapy  60  64% 
 Polytherapy  34  36% 
Use of Folic Acid  before pregnancy  9  10% 
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half of women received FA during the first 16 weeks of 
pregnancy. A survey conducted on 700 women at childbear-
ing age in four hospitals in Buenos Aires showed that 90% 
were unaware of the beneficial effects of FA and did not 
plan their pregnancy [14, 15]. In other reports the most of 
women received FA before of pregnancy [16, 17] 
In all, 90.4% of women had a normal pregnancy and de-
livery, analogous to other works [10, 11, 12, 17]. There were 
8.5% spontaneous abortions. No conclusions can be drawn 
based on this small sample size, but it is similar to reports 
from the general population in Argentina [18]. This found it 
is slight increased in relation to Eurap report [10]. 
Prenatal diagnosis was normal in all cases, although only 
59.6% of patients had an ultrasound examination; all scans 
were conducted on low resolution equipment. A number of 
different investigations showed that is essential to have the 
appropriate ultrasound equipment for detection of MCM 
[19]. 
MCM was detected in 10.6% (n=9) of newborns at birth, 
and ultrasounds were conducted on 8 mothers in this group. 
In the series of EURAP, almost 19% of cases with MCM 
were detected by ultrasound examination [10]. According to 
data from the Latin American Collaborative Study of Con-
genital Malformations [20], the MCM rates in the general 
population vary between 1.6-3.2%. The EURAP registry 
reported a total malformations rate of 5.7%. This outcome 
will be assessed in relation to exposure to individual drugs or 
drugs combinations only after sufficient data are available 
for a meaningful statistical analysis.  
Of the 86 live births, there were two cases of perinatal 
death, neither of which could be related to the presence of 
MCM. In Argentina the neonatal death rate in 2007 was at 
8.5 per 1000 healthy live births, almost double the figure 
found in countries throughout Europe and North America. 
[18]. 
Although the sample is small, given that the EC is the 
largest epilepsy center in our country and receives patients 
from different parts of the nation, we feel it can be consid-
ered representative of the behavior of women in Argentina, 
especially the low-income population.  
The results from this study provide important information 
regarding the impact of epilepsy in women who are pregnant 
or childbearing age women and are helpful in the highlight-
ing correct gaps in knowledge in this particular population 
group.  
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